WESTCHESTER COUNTY BIOSCIENCES UPDATE
Featuring news, events and industry trends
Applications Now Open: Westchester County Biosciences Accelerator

Interested in launching a bioscience venture?

The Westchester County Biosciences Accelerator is a competitive entry, 6-month long program designed to provide entrepreneurship education and regional networking to seed-stage ventures preparing to build their teams and secure funds. Innovators with therapeutics, diagnostics, medical devices, research tools, digital health and materials technology breakthroughs are invited to apply. You do not need to have already formed a company to apply.
Westchester County Biosciences Accelerator:
September 14 Info Session

Join us for this virtual information session, hosted by Albert Einstein College of Medicine and Montefiore.
  • Ask your questions in a virtual format.
  • Hear about the new program plans for 2022.
  • Learn what you need to do to submit a strong application.
  • Talk to alums from the program.
  • Talk to the program team.
Regeneron Announces Encouraging Topline Phase 2 Data on High-Dose Aflibercept in Wet Age-Related Macular Degeneration
 
Tarrytown-based Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).
Dupixent® Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Children As Young as 6-Months

Tarrytown-based Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive pivotal Phase 3 results from a trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in children aged 6-months to 5-years. The trial met its primary and all secondary endpoints, showing that Dupixent® added to standard-of-care topical corticosteroids (TCS) significantly reduced overall disease severity and improved skin clearance, itch and health-related quality of life measures at 16 weeks compared to TCS alone (placebo). Dupixent® is the first biologic medicine to show positive results in this young population and remains the only approved biologic medicine in patients 6-years and older with uncontrolled moderate-to-severe atopic dermatitis.
UPCOMING EVENTS
Capital Connections: The Lending Landscape

A virtual event featuring speakers from the New York State Small Business Development Center and Pursuit Lending. Participants will have the opportunity to learn more about the lending landscape for your business. What action steps do you need to take before applying for a loan? What do lenders look for in a successful loan application? What is the right loan for your business needs? Who is the right lender? What information do you need to provide in a loan application? Where can you find an advisor to help you through the process?
 
Date: September 14, 2021
Time: 4:00 PM
NewYork BIO Annual Meeting: Virtual & In-Person
 
Register now for the 2021 NewYorkBIO Annual Meeting! On September 27 the organization will bring biotech and life science leaders together, both online and
in person, for a full-day event. The Annual Meeting will feature panels, discussion, and other content focused on some of the most important topics in the industry, including:

  • Policy and regulatory implications surrounding Cell and Gene Therapies
  • Caring for patients with COVID19 - changing guidelines and the needs and opportunities for new therapeutics
  • Diversity, equity, and inclusion and the necessity of increased representation in therapeutic development
  • Entrepreneurs' perspective - thoughts from the CEOs of New York's emerging gene therapy companies
  • And more...

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.